Cephalon Cancer Drugs Clinical Pipeline Insight

Publish Date:- Nov-2016       No Of Pages (73)

Electronic Access - Single User License $600 Buy Now
CD-ROM Mail Delivery $900Buy Now
Hard Copy Mail Delivery $900 Buy Now
Electronic Access - Multi-User License $1000 Buy Now


“Cephalon-Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Cephaloan. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “13” cancer drugs in clinical pipeline and majority of them are in preclinical phase. There are 3 cancer drugs by Cephalon which are commercially available in the market.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“Cephalon-Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.


“Cephalon-Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Cephaloan. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “13” cancer drugs in clinical pipeline and majority of them are in preclinical phase. There are 3 cancer drugs by Cephalon which are commercially available in the market.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“Cephalon-Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.

1. Cephalon

  1.1 Business Overview

  1.2 Cephalon Cancer Pipeline Overview

 

2. Cephalon Cancer Drug in Research Phase

  2.1 Anticancer Antibody - Arana Therapeutics

 

3. Cephalon Cancer Drug in Preclinical Phase

  3.1 kinase Inhibitors - Daiichi Sankyo/Teva

  3.2 BIL 06v

  3.3 Anticancer Therapeutics and Diagnostics - Biosceptre International

  3.4 Monoclonal Antibody Therapeutics – AVEO

  3.5 CEP 37251

  3.6 VEGF Inhibitors - Circadian Technologies

  3.7 CXS 273

 

4. Cephalon Cancer Drug in Clinical Phase

  4.1 CEP 8983

 

5. Cephalon Cancer Drug in Phase-I

  5.1 RXDX 105

  5.2 BIL 010t

  5.3 CEP 37440

  5.4 Delanzomib

 

6. Marketed Cancer Drugs by Cephalon

  6.1 Bortezomib (Velcade)

  6.2 Doxorubicin Liposomal (Myocet)

  6.3 Omacetaxine Mepesuccinate (Synribo)

 

7. No Development Reported in Cancer Drugs in Clinical Pipeline

  7.1 Cytokine-Antibody Conjugated Cancer Therapeutics – Teva

  7.2 CXS 6001

  7.3 Telomere Capping Inhibitors - Gemin X

  7.4 CEP 751

  7.5 CEP 1612

  7.6 Cancer Therapeutics - Celator/Cephalon

  7.7 Antibody Therapeutics - Arana Therapeutics/XOMA

  7.8 Apoptosis Inducers - Gemin X

 

8. Discontinued in Cancer Drugs in Clinical Pipeline

  8.1 Obatoclax

  8.2 Amonafide

  8.3 CEP 7055

  8.4 CEP 11981

  8.5 RXDX 107

  8.6 CEP 2563

  8.7 CEP 5214

  8.8 Anti-Ganglioside Antibody – Arana

  8.9 Hepatocellular Carcinoma Therapy - Arana Therapeutics

  8.10 Anticancer Antibodies - EvoGenix/Viventia Biotech

  8.11 CXS 4001

  8.12 CXS 876

  8.13 PTL 03001

  8.14 E4orf4 Cancer Gene Therapy - Gemin X

  8.15 Protein Kinase Inhibitors - Cephalon/Johnson & Johnson

  8.16 Cancer Therapy - Gemin X/Phytera

  8.17 Monoclonal Antibody 32

  8.18 Anticancer Antibodies - Arana Therapeutics/NIH

 

9. Suspended in Cancer Drugs in Clinical Pipeline

  9.1 CEP 9722

  9.2 CXS 299


Figure 1-1: Cephalon Cancer Pipeline by Phase (%)

Figure 1-2: Cephalon Cancer Pipeline by Phase (Number)

Figure 1-3: Cephalon Cancer Drugs Discontinued & Suspended in Clinical Pipeline by Phase (%)

Figure 1-4: Cephalon Cancer Drugs Discontinued & Suspended in Clinical Pipeline by Phase (Number)